The third straight win for Xarelto defendants in the Xarelto MDL No. 2592 bellwether trial, boosts the defendant's stand regarding the safety and efficacy of Xarelto. Bayer released a statement saying, ''that its FDA-approved label contains accurate, science-based information on the benefits and risks of this life-saving medicine.” This decision came in by the Mississippi federal jury in favor of the defendants: J&J's Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. The plaintiff alleged that the Prothrombin Time (PT) test which is used to assess a patient's risks for bleeding, was not informed and instructed to the doctors by the manufacturers. This was opposed by the defendant's say that the PT test was not scientifically reliable.
